MRD
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Date: 8th February 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…
Date: 18th January 2024
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…
Date: 24th November 2023
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 20th October 2023
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 22nd September 2023
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of…
Date: 8th September 2023
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients…
Date: 22nd June 2023
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 12th April 2023
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the…
Date: 5th April 2023
The role of MRD in multiple myeloma
Over the last two decades, treatment approaches for multiple myeloma have significantly changed, and measurable residual disease (MRD) assessment is…
Date: 14th February 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 2nd February 2023
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 9th January 2023
